Chimerix Inc (CMRX)

$0.89

Market is closed - opens 7 PM, 29 Jul 2024

Performance

  • $0.88
    $0.91
    $0.89
    downward going graph

    1.01%

    Downside

    Day's Volatility :2.87%

    Upside

    1.87%

    downward going graph
  • $0.78
    $1.30
    $0.89
    downward going graph

    12.36%

    Downside

    52 Weeks Volatility :40.0%

    Upside

    31.54%

    downward going graph

Returns

PeriodChimerix IncSector (Health Care)Index (Russel 2000)
3 Months
-1.62%
6.5%
0.0%
6 Months
-4.77%
7.1%
0.0%
1 Year
-24.33%
9.8%
0.0%
3 Years
-87.58%
14.2%
-20.2%

Highlights

Market Capitalization
78.9M
Book Value
$1.94
Earnings Per Share (EPS)
-0.94
PEG Ratio
0.0
Wall Street Target Price
7.0
Profit Margin
0.0%
Operating Margin TTM
-232285.35%
Return On Assets TTM
-26.3%
Return On Equity TTM
-39.86%
Revenue TTM
41.0K
Revenue Per Share TTM
0.0
Quarterly Revenue Growth YOY
-99.5%
Gross Profit TTM
-36.5M
EBITDA
-95.1M
Diluted Eps TTM
-0.94
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-0.88
EPS Estimate Next Year
-1.0
EPS Estimate Current Quarter
-0.22
EPS Estimate Next Quarter
-0.23

Analyst Recommendation

Buy
    92%Buy
    7%Hold
    0
    0%Sell
Based on 13 Wall street analysts offering stock ratings for Chimerix Inc(by analysts ranked 0 to 5 stars)
Based on 13 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
12
12
12
Hold
1
1
1
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 686.52%

Current $0.89
Target $7.00

Technicals Summary

Sell

Neutral

Buy

Chimerix Inc is currently in a favorable trading position ( BUY ) according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Chimerix Inc
Chimerix Inc
0.26%
-4.77%
-24.33%
-87.58%
-74.71%
Moderna, Inc.
Moderna, Inc.
-1.67%
18.26%
-0.21%
-64.15%
752.69%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
-0.46%
13.21%
45.59%
84.19%
244.2%
Novo Nordisk A/s
Novo Nordisk A/s
-11.0%
18.31%
61.56%
186.46%
423.59%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
3.85%
14.43%
39.88%
147.45%
195.07%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Chimerix Inc
Chimerix Inc
0.48
NA
0.0
-0.88
-0.4
-0.26
NA
1.94
Moderna, Inc.
Moderna, Inc.
24.73
NA
0.0
-7.19
-0.38
-0.16
NA
33.47
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
31.35
31.35
1.46
44.44
0.15
0.08
NA
250.15
Novo Nordisk A/s
Novo Nordisk A/s
44.28
44.28
2.36
3.43
1.0
0.25
0.01
22.18
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
31.85
31.85
0.53
16.98
0.24
0.13
NA
71.8
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Chimerix Inc
Chimerix Inc
Buy
$78.9M
-74.71%
0.48
0.0%
Moderna, Inc.
Moderna, Inc.
Buy
$45.3B
752.69%
24.73
-115.82%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$116.9B
244.2%
31.35
29.45%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$572.0B
423.59%
44.28
36.55%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$126.7B
195.07%
31.85
39.46%

Insights on Chimerix Inc

  • Decreasing Revenue

    Revenue is down for the last 6 quarters, 32.55M → 4.0K (in $), with an average decrease of 75.0% per quarter

  • Decreasing Net Profit

    Netprofit is down for the last 2 quarters, -18.16M → -21.86M (in $), with an average decrease of 20.4% per quarter

  • Vs NVO

    In the last 1 year, Novo Nordisk A/s has given 61.6% return, outperforming this stock by 85.9%

  • Vs NVO

    In the last 3 years, Novo Nordisk A/s has given 186.5% return, outperforming this stock by 274.1%

Institutional Holdings

  • RA Capital Management, LLC

    9.82%

  • Monaco Asset Management

    4.88%

  • Vanguard Group Inc

    4.85%

  • Armistice Capital, LLC

    2.53%

  • Acadian Asset Management LLC

    2.43%

  • Renaissance Technologies Corp

    2.07%

Company Information

led by an experienced antiviral drug development team, chimerix is developing novel oral antiviral therapeutics with the potential to improve quality of life for patients in multiple settings, including transplant, oncology, acute care and global health. the company’s proprietary lipid technology has given rise to two clinical stage compounds, cmx001 and cmx157, which have demonstrated the potential for enhanced activity, bioavailability and safety compared to currently approved drugs. chimerix’s lead compound, cmx001, is a broad spectrum lipid acyclic nucleoside phosphonate that inhibits double-stranded dna (dsdna) viruses including cytomegalovirus (cmv), adenovirus, bk virus, herpes simplex virus and variola (smallpox). cmx001 has completed phase 2 clinical development for the prophylaxis of cmv and is in phase 2 development for the preemption and treatment of adenovirus infection in hematopoietic stem cell transplant (hsct) recipients. to date, more than 750 patients have been dosed

Organization
Chimerix Inc
Employees
72
CEO
Mr. Michael T. Andriole M.B.A.
Industry
Health Technology

Discover More

FAQs